Famotidine or omeprazole
Pro Research Analysisby 
Searched over 200M research papers
Comparative Efficacy of Famotidine and Omeprazole
Introduction to Acid Suppressants in Dogs
Famotidine and omeprazole are commonly used acid suppressants in veterinary medicine. Their efficacy in controlling intragastric pH and preventing gastric lesions has been the subject of various studies. This article synthesizes research findings on the comparative effectiveness of these two drugs in dogs.
Intragastric pH Control in Dogs
Omeprazole vs. Famotidine
Research comparing the effects of oral famotidine and two formulations of omeprazole (tablet and reformulated paste) on intragastric pH in dogs has shown that omeprazole is significantly more effective. In a study involving six healthy adult dogs, omeprazole tablets and reformulated paste maintained intragastric pH ≥3 for 63% and 54% of the time, respectively, compared to 22% for famotidine. Similarly, for pH ≥4, omeprazole formulations were effective 52% and 44% of the time, respectively, versus 14% for famotidine. This indicates that omeprazole provides superior gastric acid suppression compared to famotidine.
Prevention of Exercise-Induced Gastritis
High-Dose Famotidine vs. Omeprazole
In racing Alaskan sled dogs, high-dose famotidine (40 mg q12h) was compared to omeprazole (20 mg q24h) for preventing exercise-induced gastritis. Omeprazole significantly reduced the severity and prevalence of gastric lesions compared to high-dose famotidine. Specifically, the severity score was lower (0.4 vs. 1.2) and the prevalence of lesions was reduced (2/23 vs. 7/21) with omeprazole. This suggests that omeprazole is more effective than high-dose famotidine in preventing gastritis in highly active dogs.
Impact on Gastrointestinal Adverse Events in Dogs with Cancer
Omeprazole and Famotidine with Piroxicam
A study on dogs with cancer treated with piroxicam assessed the impact of prophylactic omeprazole and famotidine on gastrointestinal adverse events (AEs). Dogs receiving omeprazole experienced more frequent and severe GI AEs compared to those on famotidine or placebo. By day 56, 84.6% of dogs in the omeprazole group experienced GI AEs, compared to 80% in the famotidine group and 36.4% in the placebo group. This indicates that omeprazole may not be beneficial and could potentially exacerbate GI AEs in dogs undergoing cancer treatment with NSAIDs.
Rapid Onset of Action in Acid-Related Diseases
Intravenous Administration
In a study comparing single intravenous doses of omeprazole and famotidine, famotidine increased intragastric pH more rapidly than omeprazole. Famotidine maintained a higher pH for a longer duration within the first four hours post-administration. This suggests that for immediate acid suppression, famotidine may be more effective than omeprazole.
Treatment of Duodenal Ulcers
Healing Rates and Pain Relief
Omeprazole has been shown to be superior to famotidine in the healing of duodenal ulcers. In a clinical trial, omeprazole achieved higher healing rates after 2 weeks (77% vs. 40%) and 4 weeks (93% vs. 80%) of treatment compared to famotidine. Additionally, omeprazole provided more rapid relief from ulcer-related pain and reduced antacid intake . This highlights omeprazole's effectiveness in treating duodenal ulcers and providing symptomatic relief.
Conclusion
Overall, omeprazole generally provides superior acid suppression and is more effective in preventing and treating gastric lesions and duodenal ulcers compared to famotidine. However, in specific scenarios such as rapid onset of action or in dogs with cancer treated with NSAIDs, famotidine may offer certain advantages. The choice between these medications should be tailored to the specific clinical context and the individual needs of the patient.
Sources and full results
Most relevant research papers on this topic